Nt2- Dr Pestell had first protocol for our study that patient must have CCR5 present on cancers cells , this is why our very first emergency patient was refused treatment , she was not approved because of differences with our protocol ....her CCR5 was on macrophages around tumors , but not on tumors cells ..

Than Dr Pestell left , and Dr Patterson came , and he insisted that this is not the most important , the most important is if macrophages around tumors express CCR5 , so they changed protocol ..

Our first 2 patients had ..0 .. CCR5 on tumor cells , but both had high CCR5 expression on macrophages around tumors , and we know how they are doing ..

This is probably a reason that letonlimab will work for many different cancers ..


IMO as always ..